It is a universally held principle that in an equitable society all patients with a particular disease should be optimally treated for it, without regard to their age, to their place of residence, or to whom they initially present or are referred. This has recently been reaffirmed in the Policy Document produced by the Expert Advisory Group on Cancer to the Chief Medical Officers of England and Wales as one of the key principles which should govern cancer care.' However, two papers in this issue of Thorax" complement evidence published elsewhere that the management of patients with lung cancer is often suboptimal. These data, which show a very wide variation in care patterns -even between specialist services -suggest that there is an urgent need for the development and use of auditable standards.
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Variations involving the elderly Because of the overwhelming impact of tobacco consumption on a person's subsequent risk of developing lung cancer, past and present patterns of tobacco consumptions can both explain present age specific patterns of presentation and be used to predict future changes. In parts of the world where tobacco smoking was well established in the early years of the century, and where overall consumption now is beginning to fall, the mean age at presentation is rising and will continue to do so for the next 20 years or so.4 This is shown, for example, in National Registry data from the UK where there has been an increase in the mean age at presentation from 65 to 68 years between 1975 and 1990 . Predictions based upon Regional Registry data have suggested that, by the year 2000, it is likely that more than 40% of all patients with lung cancer in the UK will be aged over 75, and that an increasing proportion of these patients will be women.5
Against this background, it is a matter of great concern that there is increasing evidence that investigation and treatment rates for lung cancer are age related, despite evidence that the capacity to benefit from treatment is similar across the age bands.6 The key to the selection of appropriate treatment is accurate diagnosis, yet in a comprehensive regional survey the rate of histological confirmation for lung cancer patients increased from 61% to 82% in the period from 1976-8 to 1985-90 for patients under 60, but from only 19-4% to 39% for patients over 75. 5 Similarly, active treatment by surgery, radiotherapy, or chemotherapy increased from 59% to 69% in patients under 60 over the same period, whereas for patients over 75 the increase was from only 29% to 41%. These histological confirmation rates compare very poorly with those for other sites of cancer where it is not unusual to find rates over 90%. The Yorkshire Cancer Registry mean for all sites in 1990-2 was 81%, with the rate for lung being lowest at 64% compared with 79% for stomach cancer which also has a poor prognosis.
In the paper in this issue of Thorax by Brown et In the study by Brown et al a decision to treat actively was strongly related to whether or not a patient had a histological diagnosis, with only 5% of patients over 75 without such diagnosis receiving active treatment. It is still not clear, however, whether these low rates of histological confirmation and treatment are appropriate or not because there is strong evidence that prognosis is inversely proportional to age. The age gradient for prognosis in lung cancer was demonstrated by Rossing and Rossing8 and has been confirmed in two UK regional studies.69 In the paper by Watkin et al,9 for example, survival at six months from diagnosis in the 9771 patients who were histologically confirmed decreased from 50% in the 44 patients aged less than 40, to 40% for the 1570 patients aged 50-59, down to 20% of the 3870 patients aged more than 70 at presentation. Such differences are unlikely to be due to technical factors such as delayed registration although, paradoxically, there is some evidence to suggest that localised disease is more common as the age of presentation increases.'01' It is possible that this conclusion is incorrect and subject to a population bias in the studies. There is little evidence to support the contention sometimes made that lung cancer in the elderly usually follows a more "benign" and slowly progressive pattern ofdisease. Because of these uncertainties, there is now a very strong case for large population based studies to investigate further the factors which appear to determine these very substantial age related differences.
It has to be remembered that most elderly patients with lung cancer will die from, rather than simply with, their disease. Median survivals of only a few months have to be contrasted with life expectancies in the UK of seven years for a man aged 75 and six years for a man aged 80, and life expectancies for women of the same ages of 10 better prognosis and quality of life for patients therefore requires uniformly high standards of investigation, assessment, and decisions about treatment options. How can such changes be brought about? The problems of bringing the results of research into consistent widespread practice have been well described.2021 The use of guidelines in cancer services has shown distinct benefits in some studies2223 but not in all.24 There is also evidence for the value of treatment protocols. 25 Grimshaw and Russell, in their review of the effectiveness of clinical guidelines, concluded that they do improve clinical practice although the extent ofthe improvement varies considerably. 26 Haines and Jones20 point out that worthwhile changes are more likely when more than one approach is adopted. Guidance for the management of lung cancer is now available within the UK -for example, the report of a Working Group of the Standing Medical Advisory Committee27 and the report of a National Workshop organised in 1993 by the British Thoracic Society, the Royal College of Physicians, and the York Health Economics Consortium. 28 We are not aware of similar documents from other countries.
The variation in the patterns of management of other solid tumours in the UK has been graphically described as a "cancer lottery", by which is meant that patients' chances ofreceiving optimum or suboptimum management depends on their referral -itself a process which has been largely uninformed by any real understanding of the issues at stake.29 A recent analysis of a comprehensive registry data set for a large district health authority in the UK clearly shows that this pertains to lung cancer management as well ( practice in the UK,'9 but they are, nevertheless, very far from recommended practice.2730
The situation with respect to radiotherapy treatment is more complicated. There is good evidence from recently published British Medical Research Council studies that treatment with one or two fractions produces equivalent palliation to regimens with higher fractionation."32 In the Scottish study, however, in which registration ended in 1992, 63% of 186 patients had palliative treatment with five or more fractions. A recent audit3" has subsequently shown a much larger change in response to this evidence compared with a similar review of 1988.3' It is often assumed that most patients known to have small cell lung cancer have chemotherapy, but in the Scottish survey only 61 of 126 patients were given chemotherapy and this surprisingly low figure is, in fact, consistent with data from another region.' Only 24% of patients having chemotherapy were in any form of study although the SESLCG group has strong representation from teaching hospitals and regional cancer centres. On the other hand, several other features of the survey show a picture of rapid and high activity. For example, 87% ofpatients had a confirmed diagnosis within two weeks of referral to a physician and 68% ofpatients overall had definitive anticancer treatment.
This figure is much higher than elsewhere in the country,'
although it may reflect the selection, in the SESLCG study, of patients being referred to specialists within that group.
International comparisons It is difficult to know how these figures and practices compare with other countries. Variation in treatment with age has also been described in Canada,35 and the existence of different patterns of treatment in different places has been described in France. 36 The low rates of histological confirmation in the UK are not found in the Netherlands. 7 In terms of survival there appear to be substantial international differences. The recent Eurocare study of five year survival recorded by European registries38 shows, for example, a variation between 12% (Switzerland) and 6% (UK). However, these comparisons may well be misleading. Some of the results were from very small samples -for example, 299 in Spain -whereas the figures for England and Wales were based on 93 639 patients. Because the UK data are so strongly population based, the age distribution of patients in this survey and probably others is different. For example, the proportion of patients under 55 years and under 65 years, respectively, were 16% and 45% in the Swiss data and 9% and 35% for England and Wales, and intervention rates are highly likely to be age dependent. UK figures for one regional survey from 1988-90 showed an operative rate of 20% for patients under 60, 8% for patients aged 70-74, and only 3% for patients aged over 75.' Thus, age differences may well be reflected in the overall five year survival of a given population although age standardised relative survival data are given in the Eurocare study.
Similar strictures probably apply to the apparently higher rate of resection in the USA. Whereas the annual national summary of resections for lung cancer carried out by all UK cardiothoracic surgeons shows a stable figure of 10%,39 the resection rate reported in a national survey from the USA40 is 28% but this is derived from the tumour registries only of hospitals with approved cancer programmes.
Conclusions
Four important conclusions emerge from these studies. Firstly, careful observation of the investigation and management of lung cancer within populations yields important information which should stimulate us to ensure a higher and more uniform standard. We need to recognise that the present variability in investigation and management suggests that, at the very least, some patients are inadequately investigated and that many are not treated in accord with current knowledge. This situation is most marked in the older age groups. Whilst this state of affairs is neither unique to lung cancer within the field of oncology nor to cancer services, it does give serious cause for concern.
Secondly, there are ways in which such issues can be addressed. The preparation and publication of widely supported standards or goals for lung cancer management is overdue and needs to be considered urgently, both nationally and internationally. In the UK this matter is being considered actively by the British Thoracic Society and the Royal College of Physicians. The current government policy initiative for cancer services within the UK provides an unrivalled opportunity for such an approach, particularly if it can be done reasonably quickly.
Thirdly, there is an implication within the studies reported in this issue of Thorax that services for lung cancer need to be organised so that all patients are fully assessed by a specialist. This in turn raises questions about the training and professional development of physicians who take on this work. For other fields of cancer such people should have clear working relationships, ideally in defined teams, with key colleagues in diagnostic and treatment disciplines. Such working relationships need to be underpinned by agreed clinical protocols and by involvement in audit.
Finally, we need to cooperate internationally to put registry data on a surer footing, and to ensure that treatment and outcome information can be part of routinely collected data. Comparison within and between countries is an essential component of audit and health services research. Improved population information should act as a stimulus to further collaborative assessments as to whether particular patterns of care do, in fact, result in better overall survival of our patients.
